BridgeBio Oncology Therapeutics Stock (NASDAQ:BBOT)

Ownership Financials Chart

Previous Close

$9.11

52W Range

$7.60 - $14.87

50D Avg

$8.75

200D Avg

$10.72

Market Cap

$684.92M

Avg Vol (3M)

$346.04K

Beta

0.22

Div Yield

BBOT Company Profile

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Aug 12, 2025

Website

BBOT Performance

BBOT Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-145.82M	$-80.86M	$-64.77M
Net Income	$-134.04M	$-74.28M	$-64.70M
EBITDA	$-145.82M	$-80.66M	$-64.68M
Basic EPS	$-4.30	$0.46	-
Diluted EPS	$-4.30	$0.46	-

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
TNGX	Tango Therapeutics, Inc.
URGN	UroGen Pharma Ltd.
SEPN	Septerna, Inc.
ANAB	AnaptysBio, Inc.
OCS	Oculis Holding AG
NRIX	Nurix Therapeutics, Inc.
KOD	Kodiak Sciences Inc.
XNCR	Xencor, Inc.
MNMD	Mind Medicine (MindMed) Inc.
PHAT	Phathom Pharmaceuticals, Inc.